v3.25.4
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Feb. 13, 2025
Mar. 28, 2022
Sep. 30, 2025
Sep. 30, 2025
May 13, 2025
Dec. 31, 2024
Subsidiary, Sale of Stock [Line Items]            
Shares outstanding     49,525,970 49,525,970 2,929,000 27,601,767
Shares to be issued     490,000,000 490,000,000   490,000,000
Shares issued     49,525,970 49,525,970   27,601,767
Forward purchase agreement liability       $ 49,034    
Forward purchase agreement liability     $ 9,901 9,901   $ 0
Instaprin Pharmaceuticals Inc [Member]            
Subsidiary, Sale of Stock [Line Items]            
Assets acquired   $ 3,628,325        
Business acquistion percentage   20.00%        
Transaction costs   $ 5,000,000        
Business acquistion description   10% from sales thereafter until the entire contingent purchase price obligation is satisfied. Additionally, ten percent (10%) of the Company’s equity was to be delivered at Closing, in proportion to their equity holdings in the Company, to be issued to a Trustee for the former Instaprin Shareholders, along with an additional ten percent (10%) of the Company’s equity to be issued to Instaprin’s service providers, pursuant to a stock incentive plan to be adopted.        
Purchase Agreement [Member]            
Subsidiary, Sale of Stock [Line Items]            
Forward purchase agreement liability       49,034    
change in fair value of derivatives     39,384 39,133    
Forward purchase agreement liability     $ 9,901 $ 9,901    
Purchase Agreement [Member] | Arena Business Solutions Global SPC II Ltd [Member]            
Subsidiary, Sale of Stock [Line Items]            
Number of shares issued 100,000,000          
Shares to be issued 2,000,000          
Shares issued 893,473          
Private Placement Warrants [Member]            
Subsidiary, Sale of Stock [Line Items]            
Shares outstanding         9,763,333